静脉利多卡因治疗创伤性肋骨骨折:双盲随机对照试验(INITIATE研究计划)
这项单中心、双盲、随机对照试验纳入36例诊断为2根及以上创伤性肋骨骨折需住院的成人创伤患者,比较静脉利多卡因联合常规镇痛与安慰剂输注联合常规镇痛,持续72至96小时。主要结局为静息和活动时视觉模拟量表疼痛评分。结果显示利多卡因组活动时疼痛评分显著低于安慰剂组(7.05±1.72 vs 8.22±1.28,p=0.042),静息痛评分虽降低但未达统计学显著(3.37±2.00 vs 3.82±1.97,p=0.519)。患者满意度(8.3,IQR 7.0-9.6 vs 6.3,IQR 5.2-7.1,p=0.105)和总吗啡当量(167,IQR 60-340 vs 290,IQR 148-390,p=0.194)在利多卡因组更低但均未达统计学显著。作者认为利多卡因对创伤性肋骨骨折患者具有有益镇痛效果,未来需评估其减少镇痛不足所致患者重要结局的能力。
要点
- 对于2根及以上创伤性肋骨骨折需住院的成人创伤患者,静脉利多卡因联合常规镇痛72至96小时可显著降低活动时疼痛评分(7.05±1.72 vs 8.22±1.28,p=0.042)。
- 静息痛评分在利多卡因组虽降低但未达统计学显著(3.37±2.00 vs 3.82±1.97,p=0.519)。
- 患者满意度在利多卡因组更高但未达统计学显著(8.3,IQR 7.0-9.6 vs 6.3,IQR 5.2-7.1,p=0.105)。
- 总吗啡当量在利多卡因组更低但未达统计学显著(167,IQR 60-340 vs 290,IQR 148-390,p=0.194)。
- 作者认为利多卡因对创伤性肋骨骨折患者具有有益镇痛效果,未来需评估其减少镇痛不足所致患者重要结局的能力。
适用人群与场景
- 成人创伤患者,诊断为2根及以上创伤性肋骨骨折,需要住院治疗。
处置流程与药物剂量
- 静脉利多卡因联合常规镇痛药,持续72至96小时;安慰剂为安慰剂输注联合常规镇痛药。
研究设计与关键结果
- 单中心、双盲、随机对照试验,纳入36例成人创伤性肋骨骨折患者,随机分配至静脉利多卡因联合常规镇痛组或安慰剂输注联合常规镇痛组,持续72至96小时。
- 主要结局活动时视觉模拟量表疼痛评分:利多卡因组7.05±1.72 vs 安慰剂组8.22±1.28,p=0.042,利多卡因组显著降低。
- 静息时视觉模拟量表疼痛评分:利多卡因组3.37±2.00 vs 安慰剂组3.82±1.97,p=0.519,差异未达统计学显著。
- 患者满意度:利多卡因组8.3(IQR 7.0-9.6) vs 安慰剂组6.3(IQR 5.2-7.1),p=0.105,差异未达统计学显著。
- 总吗啡当量:利多卡因组167(IQR 60-340) vs 安慰剂组290(IQR 148-390),p=0.194,差异未达统计学显著。
- 研究把握度设定为检测疼痛评分20%的下降,该幅度被认为具有临床意义。
证据类型、等级与局限
- 证据类型:单中心、双盲、随机对照试验。
- 证据等级:治疗/护理管理;Level II。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些结果表明利多卡因对创伤性肋骨骨折患者具有有益镇痛效果。
- 作者指出,未来工作需要评估利多卡因减少镇痛不足所致患者重要结局的能力。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Traumatic rib fractures (TRFs) are common with a 10% incidence in all trauma patients and are associated with significant morbidity and mortality. Adequate analgesia is paramount for preventing pulmonary complications and death. Evidence exists for intravenous (IV) lidocaine's effectiveness and safety in postoperative thoracic and abdominal surgery, and we hypothesized that it would be effective in patients with TRFs.
METHODS: We conducted a single-center, double-blind, randomized control trial comparing IV lidocaine plus usual analgesics to placebo infusion plus usual analgesics for 72 hours to 96 hours. Participants were adult trauma patients diagnosed with two or more TRFs requiring hospital admission. The primary outcome was mean pain score at rest and with movement, as measured on the visual analog scale. Secondary outcomes included patient satisfaction and opioid requirements (standardized total morphine equivalents). The study was powered to detect a 20% reduction in pain scores, which has been deemed clinically meaningful.
RESULTS: Thirty-six patients were enrolled and randomized to IV lidocaine or placebo. Comparison of the mean visual analog scale pain scores demonstrated significant pain reduction with movement in the lidocaine group compared with placebo (7.05 ± 1.72 vs. 8.22 ± 1.28, p = 0.042). Although pain scores at rest were reduced in the lidocaine group, this difference was not statistically significant (3.37 ± 2.00 vs. 3.82 ± 1.97; p = 0.519). Patient satisfaction was higher in the lidocaine group than the placebo group, although this did not reach statistical significance (8.3; interquartile range [IQR], 7.0-9.6 vs. 6.3; IQR, 5.2-7.1; p = 0.105). Total morphine equivalents were lower in the lidocaine group than the placebo group, but this difference did not reach statistical significance (167; IQR, 60-340 vs. 290; IQR 148-390; p = 0.194).
CONCLUSION: These results demonstrate that lidocaine has a beneficial analgesic effect in patients with TRFs. Future work is needed to evaluate lidocaine's ability to reduce patient important consequences of inadequate analgesia.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level II.
参考来源
- Patton P, Vogt K, Priestap F, et al. Intravenous lidocaine for the management of traumatic rib fractures: A double-blind randomized controlled trial (INITIATE program of research). J Trauma Acute Care Surg. 2022. PMID: 35137728. doi:10.1097/TA.0000000000003562
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。